We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Craig Bradley profile page

AI Operations Manager

at LabX Media Group

Craig Bradley has a strong academic background in human biology, cardiovascular sciences and biomedical engineering. Since 2025, he has been working with LabX Media Group as an SEO Editor. Craig can be reached at cbradley@labx.com.

Education

University of Glasgow

University of Strathclyde

Areas of Expertise

Impedance Spectroscopy

Got a Question for Craig Bradley?

Get in touch using the contact form linked here and we'll get back to you shortly.

Content Written By, Reviewed By, or Featuring Craig Bradley

Total: 43

Scientist monitoring real-time bioprocess data on PAT dashboard screens in a biomanufacturing facility.

Next-Generation Process Analytics and Industrial QC Testing

Process analytical technology is transforming biomanufacturing quality control by enabling real-time, data-driven decisions at every stage of production.

A large bioinformatics workstation with dual monitors in a modern genomics research facility.

Integrating Screening and Omics Data in Drug Discovery

How integrating screening and omics data improves target identification, hit contextualization, and translational prediction in drug discovery.

Dual-monitor workstation in a drug discovery lab displaying HTS assay heatmap and AI molecular network visualization.

AI vs Traditional Statistical Analysis in HTS

AI vs statistical screening in HTS: how machine learning and traditional methods compare for hit identification and assay data analysis.

Microfluidic chip channels under fluorescence microscopy during high-throughput compound screening

Microfluidics for High-Throughput Screening

Microfluidic HTS platforms are transforming drug discovery by enabling nanoliter-scale assays with unprecedented throughput and reduced reagent costs.

Fluorescence micrograph of a multicellular tumor spheroid in a 3D cell culture drug screening assay.

3D Cell Culture Platforms for Drug Screening

3D cell culture screening platforms are advancing drug discovery by delivering physiologically relevant models that better predict clinical outcomes than 2D assays.

Scientist screening antibody candidates on a high-throughput biologics discovery platform in a laboratory.

Screening Platforms for Biologics and Antibody Discovery

Biologics screening platforms are accelerating antibody discovery through display technologies, single-cell methods, and functional assays.

Zebrafish larvae arrayed in a multiwell plate for in vivo high-throughput drug screening.

In Vivo High-Throughput Screening Approaches

In vivo high throughput screening with whole-organism models is bridging the gap between in vitro assays and clinical translation in drug discovery.

Scientist examining patient-derived cell cultures used in rare disease drug screening and orphan target discovery.

Screening Strategies for Rare Disease Targets

Rare disease screening leverages phenotypic assays, iPSC models, and AI-driven repurposing to tackle the vast unmet need in orphan disease targets.

Luminescent 3D human organoids in hydrogel within a laboratory microtiter plate.

Organoid Screening Models in Drug Discovery

Organoid screening platforms are transforming drug discovery by providing physiologically relevant 3D models that improve translational accuracy.

Visualization of a modern integrated laboratory station where a scientist works with CRISPR gene editing

Emerging Screening Technologies in Drug Discovery

Explore emerging screening technologies in drug discovery. Enhance laboratory workflows with advanced models, CRISPR, and microfluidics. Read the full guide.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter